Phani Sekhar of Angel Broking told CNBC-TV18, "Wyeth from a long-term portfolio makes a lot of sense, because the swap ratio of 10:7 is in my opinion quite fair to Wyeth shareholders. This combined entity Pfizer-Wyeth is really going to be a force to reckon with in the market."
"Wyeth by itself was facing certain headwinds in the form of the new pricing policy being announced by the government of India. We had seen the impact of that on the result of the second quarter also, but I think with Pfizer you will have a diversified product mix. That is going to be certainly beneficial for Wyeth shareholders and there is a merger arbitrage out there also. I guess purely from an investing point of view there is no reason why the investors should think of exiting Wyeth," he added.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
